Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(2):90-91; doi:10.1093/jnci/96.2.90
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Improved Paclitaxel Formulation Hints at New Chemotherapy Approach

Ken Garber

The first 150 words of the full text of this article appear below.

The 2003 San Antonio Breast Cancer Symposium was a vindication of sorts for an embattled biotechnology company and its controversial founder. The Santa Monica, Calif.-based American Pharmaceutical Partners (APP) presented highly anticipated phase III data for ABI-007, a new paclitaxel formulation, in metastatic breast cancer. Going head-to-head against the standard paclitaxel formulation Taxol, ABI-007 (trade name Abraxane) roughly doubled patient response rates and achieved longer tumor time-to-progression at no cost in toxicity. Company founder and chief executive officer Patrick Soon-Shiong, M.D., expects to apply for U.S. Food and Drug Administration approval for ABI-007 early in 2004.

APP’s drug reformulation ambitions go beyond paclitaxel. At the symposium, the company also unveiled a provocative theory to explain why its albumin nanoparticle-based formulation performed so much better than Taxol. The theory, involving a novel transport mechanism that preferentially targets tumors, could have broad implications for delivery of other cancer drugs. APP’s theory "is . . . [Full Text of this Article]

Making a Better Taxol

Hitchhiking Into Tumors

New Hope for High Dose?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?